Immunitas
immunitastx.com
Actively hiring
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
Report
Immunitas Presents Phase 1/2a Data Highlighting Anti-Tumor Activity of Novel Immunotherapy IMT-009 at AACR 2026 Annual Meeting
Immunitas Therapeutics ("Immunitas"), a clinical stage precision immunotherapy company committed to discovering and developing novel, antibody-based therapeutics for patients with autoimmune diseases and cancer, today presented Phase 1/2a clinical data fo
Read more
Report
Immunitas Presents Phase 1/2a Data Highlighting Anti-Tumor Activity of Novel Immunotherapy IMT-009 at AACR 2026 Annual Meeting
Read more
Report
Immunitas Therapeutics to Present Clinical Data Supporting Monotherapy and Combination Treatment Potential of IMT-009 at the AACR 2026 Annual Meeting
Immunitas Therapeutics ("Immunitas"), a clinical stage precision immunotherapy company committed to discovering and developing novel, antibody-based therapeutics for patients with autoimmune diseases and cancer, today announced it will present clinical da
Read more
Report
Immunitas Therapeutics Presents Preclinical Data Supporting Combination Of IMT-009 With Anti-PD1 Immunotherapy At The AACR 2024 Annual Meeting
Immunitas Therapeutics Presents Preclinical Data Supporting Combination Of IMT-009 With Anti-PD1 Immunotherapy At The AACR 2024 Annual Meeting. Preclinical data expand potential of IMT-009, confirming presence of CD161 expressing T cells in anti-PD1 non-r
Read more
Report
Immunitas Therapeutics Presents New Data For TLR9 Agonist Conjugate At The Society For Immunotherapy Of Cancer 2023 Annual Meeting
Immunitas Therapeutics Presents New Data For TLR9 Agonist Conjugate At The Society For Immunotherapy Of Cancer 2023 Annual Meeting. In vitro proof-of-concept data shows effective delivery of CpG to endosomal TLR9 via anti CLEC2D antibody, resulting in sus
Read more
Report